Q-omics provides the consensus-scored INTS4 profile across patient tissues and cancer cell-line models. INTS4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INTS4 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, INTS4 protein abundance shows 24,500 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, BLCA, and GBM as cancer lineages where INTS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INTS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INTS4 survival associations across molecular data types. INTS4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INTS4 RNA expression–survival associations across cancer types. High INTS4 expression shows unfavorable associations in ACC, LIHC and PAAD, but favorable associations in READ, KIRC and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INTS4 RNA expression.
This table summarizes INTS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for INTS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INTS4 shows higher tumor expression in BLCA, HNSC, LIHC, STAD, LUAD and LUSC. The BLCA box plot shows higher INTS4 RNA expression in tumor versus normal tissue (log2 FC = +0.843, t-test p < 0.001).
This table shows molecular features associated with INTS4 in patient tissues and cancer cell lines. In patient samples, INTS4 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, INTS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
